Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab

Clin Exp Dermatol. 2024 Mar 21;49(4):399-400. doi: 10.1093/ced/llad412.

Authors

Elena Biancamaria Mariotti¹, Alberto Corrà¹, Cristina Aimo¹, Valentina Ruffo di Calabria¹, Lavinia Quintarelli², Alice Verdelli², Marzia Caproni²

Affiliations

¹ Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
² Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, USL Toscana Centre, European Reference Network-Skin Member, University of Florence, Florence, Italy.

PMID: 38011325
DOI: 10.1093/ced/llad412

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Pemphigoid, Bullous* / chemically induced
Pemphigoid, Bullous* / drug therapy

Substances

dupilumab
Antibodies, Monoclonal, Humanized